New Parkinson's drug enters first human safety trial

NCT ID NCT07422675

Recruiting now Symptom relief Sponsor: Serina Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of SER-252 in 40 people with Parkinson's disease who experience motor fluctuations (times when symptoms worsen). The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo, and researchers monitor side effects and drug levels over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PARKINSON'S DISEASE PARKINSON DISEASE (DISORDER)

Contacts and locations

Locations

CMAX
RECRUITING

Adelaide, South Australia, 5000, Australia
K2 Medical Research LLC
RECRUITING

Maitland, Florida, 32751, United States
Monash
RECRUITING

Melbourne, Victoria, 3170, Australia
Quest Research Institute
RECRUITING

Farmington Hills, Michigan, 28555, United States
Rocky Mountain Clinical Research
NOT_YET_RECRUITING

Englewood, Colorado, 80113, United States
Velocity Clinical Research
RECRUITING

Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.